Analytical Data
-
Gene name
ophA1
- Application
-
Alternative Names
/
-
Species
Burkholderia cepacia
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P33164
-
Expression Region
2-322aa
-
Molecular Weight
39.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OphA1 is a significant protein associated with the virulence of various pathogens, particularly in the context of infectious diseases. Its role as a potential target for vaccine development and therapeutic interventions has garnered increasing attention in recent years. Research into OphA1 recombinant proteins has focused on elucidating their structural and functional properties to understand how they contribute to pathogenicity. The study of OphA1 can provide insights into the mechanisms by which bacteria evade the host immune response, making it a vital candidate for developing novel immunological strategies. The technology for producing recombinant proteins has advanced, enabling researchers to generate large quantities of OphA1 for further investigation. By exploring the immunogenicity of OphA1, scientists aim to assess its potential as a vaccine candidate, which could lead to effective preventive measures against infections. Additionally, the characterization of OphA1's interactions with host cells could reveal new pathways for therapeutic targets, enhancing our overall understanding of host-pathogen dynamics. Thus, ongoing studies into OphA1 recombinant proteins are crucial for advancing medical research and designing innovative strategies to combat infectious diseases.
